SOUTH SAN FRANCISCO, Calif. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in investor meetings and
Third Q uarter T otal R evenue I n creased 50 P ercent to $ 39 .9 M illion Third Q uarter P roduct and Service R evenue I ncreased 34 P ercent to $35 . 3 M illion D riven by COVID-19 T esting GAAP N et L oss in the T hird Q uarter Was $6.0 M illion ; Non-GAAP N et I ncome W as $2.5
Patients Receive Results, Education and Next Steps on Their Mobile Phones to Prevent Further Spread of the Disease SOUTH SAN FRANCISCO, Calif. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through
25 Trials Utilizing Mass Cytometry Initiated in 2020 SOUTH SAN FRANCISCO, Calif. , Nov. 03, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that its mass
Global Pioneer in Direct-to-Consumer Genomic Testing Chooses Fluidigm Saliva-Based Solution Fluidigm Powered Testing Service to be Rolled Out in Seven European Countries SOUTH SAN FRANCISCO, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative
Fluidigm COVID-19 Campus Safeguard Program Improves Availability of Non i nvasive, Saliva-Based SARS-CoV-2 Test s for Higher Education Institutions High-Throughput , Integrated Testing Platform and Reliable Supply Chain SOUTH SAN FRANCISCO, Calif. , Oct.
SOUTH SAN FRANCISCO, Calif. , Oct. 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2020 financial results on Thursday,
CANCERPREV Cross-Disciplinary Program Expands Knowledge of Cancer Development to Deliver New Insights into Prevention Strategies Principal Focus on Advancing Understanding of Breast and Skin Cancer Risks SOUTH SAN FRANCISCO, Calif. , Sept. 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation
Regional CLIA-Certified Labs among Growing Number of Customers Expanding SARS-CoV-2 Testing with Fluidigm Technology SOUTH SAN FRANCISCO, Calif. , Sept. 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through
Virtual Event Showcases CyTOF Technology and Its Use in High-Parameter Suspension Mass Cytometry and Imaging Mass Cytometry Leading Academic and Pharma Researchers Detail Latest CyTOF Based Discoveries in Infectious Disease, Immunology and the Tumor Microenvironment SOUTH SAN FRANCISCO, Calif.
